10
October
2014
|
00:00
Europe/Amsterdam

BIOTRONIK to Offer New Treatment Options in France with Release of Orsiro Drug-Eluting Stent

Launch of Industry’s First Hybrid DES System Marks Expansion of the Proven Hybrid Model to Treat a Wider Range of Lesions

PARIS, France, October 10, 2014—BIOTRONIK, a leading manufacturer of cardiovascular medical technology, today announced the market release of Orsiro, the industry’s first hybrid Drug-Eluting Stent (DES) combining an active BIOlute coating and a passive proBIO coating. The release comes after a succession of studies demonstrating Orsiro’s safety and efficiency in the treatment of discrete de-novo stenotic lesions and in-stent restenotic lesions.

Two high profile studies, BIOFLOW-II and BIOFLOW-III, showed Orsiro performing as best in class. BIOFLOW-II was a prospective, international, multi-center, randomized trial evaluating the safety and efficacy of Orsiro compared with Xience Prime. The BIOFLOW-II and -III subgroup analyses released this year demonstrated the top performance of Orsiro in the treatment of patients with small vessel disease and complex B2/C lesions, respectively. The results of the much larger investigator-initiated BIOSCIENCE trial, which compared Orsiro with Xience Prime in a larger patient population more reflective of routine clinical practice, have further confirmed the ultra-thin Orsiro as best in class. The BIOSCIENCE results were published in the prestigious general medical journal The Lancet.

“We have been tracking Orsiro closely as its use widens globally, waiting for it to come to us,” said Prof. Didier Carrié, Interventional Cardiologist, University Hospital of Toulouse, France, who was among the first to implant one of the new stents. “It is of great benefit to my practice that I am now able to offer treatment with Orsiro to patients here in France. Thanks to its bioabsorbable polymer coating, it is the best chance we have at minimizing adverse events.”

Based on the PRO-Kinetic Energy platform, Orsiro offers exceptional flexibility without compromising scaffolding or fatigue resistance, while a thinner 60 µm strut design ensures minimal vessel injury. The stent will be offered in up to 40 mm lengths, making it one of the longest drug-eluting stents on the market. Its design allows for stent expansion without affecting the performance of the polymer coating, ensuring improved patient outcome when treating coronary artery stenosis, even in patients with particularly long lesions.

“We are happy to announce that the Orsiro hybrid DES, one of three stent systems in the BIOTRONIK Masterpieces portfolio along with the PRO-Kinetic Energy bare metal stent and the PK Papyrus covered stent, will now be available to yet another patient population that needs it,” commented Dr. Alexander Uhl, Vice President of Marketing, BIOTRONIK Vascular Intervention. “Physicians rely on top performing tools for each and every procedure. We see the launch of Orsiro in France as a crucial step towards giving an even greater number of physicians worldwide the chance to work with a tool that we consider a Masterpiece.”

    About BIOTRONIK:

    BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.